TriSalus Life Sciences, Inc. provided preliminary unaudited revenue guidance for the fourth quarter and full year ended December 31, 2023 and full year 2024. For the fourth quarter 2023, the company expects revenue to be approximately $5.7 million for the fourth quarter of 2023. This represents growth of approximately 77% versus the fourth quarter of 2022.

For the full year 2023, the company expects to report revenue of approximately $18.5 million. This represents growth of approximately 49% versus the full year 2022.

The company also provided revenue guidance for the Full Year 2024. The Company expects this strong momentum will continue and expects sales to grow in excess of 50% in 2024.